1. Company overview & snapshot

• Vivimed is a listed Indian pharma company that historically operated across both specialty chemicals and pharmaceuticals. Its more recent public materials emphasize a stronger finished dosage formulations (FDF) orientation rather than the older diversified chemistry story.
• The most important correction versus the outreach kit is this: Vivimed’s current website describes the Kashipur plant as an FDF site manufacturing non-sterile syrups, tablets, capsules, external creams, and lotions, not clearly as a heavy API/intermediates synthesis block.
• Public site and legacy investor material both confirm Kashipur as a real operating manufacturing location with WHO GMP and ISO 9001 / ISO 14001 / OHSAS 18001 credentials.
• Recent public signals are mixed:
  • The company advertised a Unit Plant Head - Pharmaceutical Manufacturing role in May 2026, which suggests active management churn or a reset.
  • Much more importantly, Vivimed entered CIRP in April 2026 after an NCLT Bengaluru admission order. This materially changes account risk and timing.
  • Public labor-reporting also points to wage/PF stress at the Kashipur plant during 2026.
• Stamped takeaway: there may still be a useful plant-level utility-saving conversation here, but this is no longer a clean “healthy plant P&L optimization” account. It is a restructuring-sensitive opportunity.

2. Energy profile

• DISCOM: Very likely UPCL for Kashipur, Uttarakhand. Verify the exact tariff category and whether the site is on a direct industrial HT connection.
• Estimated bill band: Low-to-medium confidence Band A. A multi-format FDF plant with HVAC, compressed air, purified water, and packaging can absolutely have a meaningful bill, but the public record does not prove Rs 30L+/month.
• Current best public view of major loads:
  • HVAC and environmental conditioning
  • Compressors and utility air
  • Tablet/capsule/syrup/cream production support systems
  • Water systems, pumps, and packaging lines
  • Possibly boilers or hot-water systems, though that is not clearly public
• ISO 50001 / EnMS / sustainability signals:
  • Public signals support ISO 9001, ISO 14001, OHSAS 18001, and WHO GMP.
  • No public ISO 50001 evidence found.
  • No strong current public energy-management narrative found, unlike Emami or Otsuka.
• Likely Stamped-relevant pain points, if the plant is running steadily:
  • HVAC and compressor baseload that does not track actual throughput
  • Demand spikes from overlapping production and packaging windows
  • Hidden off-shift utility waste
  • Utility cost drift during partial utilization or turnaround periods

3. Operations, equipment & digital stack

• Public information now suggests Kashipur is better understood as a pharmaceutical formulations site rather than an energy-intensive API synthesis plant.
• Likely operations include:
  • syrup and liquid preparation
  • tablet and capsule manufacturing
  • creams and lotion filling/packaging
  • QA / compliance-heavy documentation workflows
• That means Stamped’s technical angle is different here:
  • less about reactor idle-hold and thermic sequencing
  • more about HVAC, compressors, packaging overlap, and utility baseload optimization
• Digital and compliance maturity are likely decent because of WHO GMP and pharma QA requirements, but no public SCADA/EMS detail was found.
• The largest operational unknown is current plant utilization after CIRP. A read-only utility optimization pilot only makes sense if production is active enough to generate a meaningful baseline and savings verification window.

4. Stamped Energy fit analysis

• Why this is a conditional fit: if Kashipur is operating at meaningful throughput, Stamped can still help on utility-bill optimization, especially around HVAC, compressed air, shift scheduling, and off-shift waste.
• Why this is weaker than some other Band A targets: the site may be less energy-intense than a specialty-chemical synthesis plant, and insolvency creates approval, budget, and execution friction.
• Best entry angle: cash recovery and no-capex utility leakage, not transformation. The strongest message is likely “read-only savings verification with low effort during a constrained operating period.”
• Stamped proof points that matter here:
  • no hardware-heavy capex
  • no write access into validated systems
  • bill-verified savings in 90 days
  • useful in partially constrained operations where every rupee matters
• Likely alternatives or blockers:
  • IRP / restructuring control over spend and vendor onboarding
  • plant leadership transition
  • low current utilization making measurement noisy
  • internal focus on survival, supply continuity, and compliance rather than optimization

5. Before you reach out

• First verify whether the Kashipur plant is running, at what utilization, and who currently has authority to approve even a low-risk pilot.
• Do not lead with “batch synthesis” or reactor optimization; public evidence now points more strongly to FDF manufacturing.
• Ask whether the biggest utility pain is HVAC, compressors, off-shift baseload, or demand charges.
• Confirm monthly UPCL bill, sanctioned demand, and whether the site has any captive/DG backup running frequently because of production instability.
• If there is a new or incoming plant head, position the pilot as a quick diagnostic layer that gives them a clean utility-cost baseline.
• Landmines:
  • CIRP and moratorium may block or slow new vendor decisions
  • public distress signals could make the team suspicious of anything non-essential
  • wrong process framing will immediately reduce credibility

6. Risks, flags & sources

• Data-quality flags:
  • The outreach kit’s “batch synthesis” framing appears stale versus current website evidence.
  • No public electricity bill or sanctioned-demand data found.
  • No public ISO 50001 signal found.
  • CIRP may make the account temporarily unattractive despite process fit.
• Sources consulted:
  • https://www.vivimedlabs.com/finished-dosage-formulations/
  • https://www.vivimedlabs.com/wp-content/uploads/2024/12/FY2024-Annual-Report.pdf
  • https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/11/8308cdfb-8aa6-49fa-a5de-42f1da98abf2.pdf
  • https://www.bseindia.com/xml-data/corpfiling/AttachHis/cd870e56-e39e-4bf5-97e6-8c1ce1b29c0a.pdf
  • https://www.livelawbiz.com/nclt/national-company-law-tribunal-bengaluru-admits-insolvency-petition-against-vivimed-labs-530797
  • https://www.livehindustan.com/uttarakhand/kashipur/story-workers-protest-for-april-wages-and-pf-at-vivi-med-company-in-kashipur-201779886868971.html